Practical management of toxicities associated with bosutinib in patients with Philadelphia chromosome-positive chronic myeloid leukemia.

Abstract

Bosutinib (SKI-606) is an oral, dual Src/Abl tyrosine kinase inhibitor (TKI) approved for treatment of patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) that is resistant or intolerant to prior TKI therapy or for whom other TKIs are not appropriate choices. The objective of this review is to provide a longitudinal summary of toxicities that may arise during treatment with second-line or later bosutinib in patients with Ph+ chronic phase CML and to provide strategies for managing these toxicities. As bosutinib is not currently indicated for newly diagnosed CML, toxicities associated with first-line treatment are not reviewed. Recognition and optimal management of these toxicities can facilitate patient compliance and affect treatment outcomes.

• Authors: H J Khoury, C Gambacorti-Passerini, T H Brümmendorf
• Journal: Annals of oncology : official journal of the European Society for Medical Oncology (Ann Oncol) Vol. 29 Issue 3 Pg. 578-587 (03 01 2018) ISSN: 1569-8041 [Electronic] England
• PMID: 29385394 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)

Chemical References

• Aniline Compounds
• Antineoplastic Agents
• Nitriles
• Quinolines
• bosutinib

Topics

• Aniline Compounds (adverse effects)
• Antineoplastic Agents (adverse effects)
• Humans
• Leukemia, Myelogenous, Chronic, BCR-ABL Positive (drug therapy)
• Nitriles (adverse effects)
• Quinolines (adverse effects)
• Salvage Therapy (adverse effects, methods)